Onyx Pharmaceuticals (NASDAQ:ONXX) saw its shares rise over 15 percent Monday on reports the oncology-focused pharmaceutical company is considering a potential sale.Shares of the company, which is responsible for liver and kidney cancer treatment Nexavar, hiked 15.74 percent to $43.61, as of 3:52 pm EDT.Earlier this month, the California-based company released less-than-stellar third quarter results, posting a $36.86 million loss, or $0.58 loss per share, compared to profits of $41.5 million, or $0.66 per share, in the year-ago period.It also reported no revenues from license agreements in the quarter, resulting in a 39 percent decline in revenues, to $75.04 million.President and CEO Dr. N. Anthony Coles said that Onyx would move forward with its oncology platforms - kinase inhibition, and proteasome inhibition.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment